好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characteristics of and Treatment Patterns Among Pediatric Patients with Post-traumatic Headache in a Pediatric Neurology Setting
Headache
P4 - Poster Session 4 (11:45 AM-12:45 PM)
12-009

To characterize pediatric neurologists’ prescribing habits for preventive treatment of post-traumatic headache (PTH) in children.

PTH is common after concussion, however there are no evidence-based treatments. Experts have recommended treating PTH like the primary headache disorder it most resembles, though this approach has limitations.

A single-center retrospective chart review included youth aged 8 - 17 years old with PTH who were seen in general neurology or headache clinics within 120 days of their concussion. Demographics, days post-injury, headache features, and past medical history were captured, as was treatment with a nutraceutical (NC) or prescription preventive medication (PM). Data were analyzed using univariate binomial regression analyses and descriptive methods.

Of 142 participants, 43% were recommended a NC, 27% got a PM, 5.6% got both, and 30% were not recommended a preventive. 80% had migraine-like headaches. Participants who received any preventive were more likely to be further out from their concussion (OR 1.01, p=0.023), have greater headache-related disability (OR 1.48 for each increase in disability grade, p=0.009), more frequent bad headache days (OR 1.36 for every increased frequency category, p=0.002), or have a continuous headache (OR 2.97 versus intermittent, p=0.003). Of PM recipients, 23/39 got amitriptyline, and 9/39 received topiramate. NC recipients got magnesium (50/61), riboflavin (34/61), or melatonin (12/61), often in combination (34/61). Sensitivity analysis of NC vs. PM revealed those who were older, had a higher headache burden, and had medication overuse were more likely to receive a PM. Of those with high headache frequency and headache-related disability, 68.5% were offered a preventive, but 31.5% were not.

Increased headache burden and symptom duration predicted recommendation of a preventive medication, mirroring standard care for migraine prevention, though there is room for practice improvement. Amitriptyline was the most utilized PM, and represents the most studied medication for PTH in children.

Authors/Disclosures
Caroline Gentile Kruse, MD (Hospital of the University of PA)
PRESENTER
Dr. Gentile Kruse has nothing to disclose.
Ryan Shah Ryan Shah has nothing to disclose.
Soumyaa Das No disclosure on file
Blanca Marquez de Prado An immediate family member of Blanca Marquez de Prado has stock in Latus Bio. An immediate family member of Blanca Marquez de Prado has received intellectual property interests from a discovery or technology relating to health care.
Nichelle Raj Nichelle Raj has nothing to disclose.
Morgan Evans (Children's Hospital of Philadelphia) Morgan Evans has nothing to disclose.
Pratishtha Panigrahi (Children's Hospital of Philadelphia) No disclosure on file
Andrew D. Hershey, MD, PhD, FAAN, FAHS, FAAN The institution of Dr. Hershey has received personal compensation in the range of $0-$499 for serving as a Consultant for Amgen. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Upsher-Smith. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Hershey has received research support from Amgen. The institution of Dr. Hershey has received research support from NIH, NINDS. The institution of Dr. Hershey has received research support from Bioahaven. The institution of Dr. Hershey has received research support from Upsher-Smith. Dr. Hershey has received publishing royalties from a publication relating to health care.
Christina Master, MD, FAAP, CAQSM (Children's Hospital of Philadelphia) The institution of Dr. Master has received research support from NIH. The institution of Dr. Master has received research support from DoD. The institution of Dr. Master has received research support from AMSSM. The institution of Dr. Master has received research support from PA Department of Health. Dr. Master has received intellectual property interests from a discovery or technology relating to health care. Dr. Master has received intellectual property interests from a discovery or technology relating to health care. Dr. Master has received intellectual property interests from a discovery or technology relating to health care.
Christina Szperka (Pediatric Headache Program and Department of Neurology, Perelman School of Medic) No disclosure on file
Carlyn Patterson Gentile, MD The institution of Dr. Patterson Gentile has received research support from NIH/NINDS. The institution of Dr. Patterson Gentile has received research support from Children's Hospital of Philadelphia. Dr. Patterson Gentile has received personal compensation in the range of $500-$4,999 for serving as a Faculty, Annual Scientific Meeting, Scottsdale Meeting with American Headache Society. Dr. Patterson Gentile has received personal compensation in the range of $5,000-$9,999 for serving as a Early Career Awardee with American Headache Society. Dr. Patterson Gentile has received personal compensation in the range of $0-$499 for serving as a Research Prize Awardee and travel expense coverage with NIH Pain Consortium. Dr. Patterson Gentile has received personal compensation in the range of $500-$4,999 for serving as a Faculty, Speaker with Headache Cooperative of New England. Dr. Patterson Gentile has received personal compensation in the range of $500-$4,999 for serving as a Speaker, Awardee with 好色先生.